

Complete Summary

GUIDELINE TITLE

Symptom severity assessment of allergic rhinitis: part 1.

BIBLIOGRAPHIC SOURCE(S)

Spector SL, Nicklas RA, Chapman JA, Bernstein IL, Berger WE, Blessing-Moore J, Dykewicz MS, Fineman SM, Lee RE, Li JT, Portnoy JM, Schuller DE, Lang D, Tilles SA. Symptom severity assessment of allergic rhinitis: part 1. *Ann Allergy Asthma Immunol* 2003 Aug; 91(2): 105-14. [14 references] [PubMed](#)

GUIDELINE STATUS

This is the current release of the guideline.

COMPLETE SUMMARY CONTENT

SCOPE
 METHODOLOGY - including Rating Scheme and Cost Analysis
 RECOMMENDATIONS
 EVIDENCE SUPPORTING THE RECOMMENDATIONS
 BENEFITS/HARMS OF IMPLEMENTING THE GUIDELINE RECOMMENDATIONS
 QUALIFYING STATEMENTS
 IMPLEMENTATION OF THE GUIDELINE
 INSTITUTE OF MEDICINE (IOM) NATIONAL HEALTHCARE QUALITY REPORT
 CATEGORIES
 IDENTIFYING INFORMATION AND AVAILABILITY
 DISCLAIMER

SCOPE

DISEASE/CONDITION(S)

Allergic rhinitis

GUIDELINE CATEGORY

Evaluation

CLINICAL SPECIALTY

Allergy and Immunology
 Family Practice
 Internal Medicine
 Pediatrics

INTENDED USERS

Physicians

GUIDELINE OBJECTIVE(S)

To provide practice parameters for the symptom severity assessment of allergic rhinitis

TARGET POPULATION

Adults and children with allergic rhinitis

INTERVENTIONS AND PRACTICES CONSIDERED

Evaluation

1. Individual assessment of symptom severity using a 7-point visual analog scale
2. Identify confounding variables
3. Objective measurement of symptoms including:
 - Episodes of sneezing
 - Number of sneezes per episode
 - Amount of nasal tissue used during a given period
 - Amount of swelling on physical examination and/or anterior rhinoscopy
 - Various rhinometric techniques
4. Assessment on non-nasal symptom severity using a 7-point visual analog scale
5. Global assessment of symptom severity
6. Disease-specific quality-of-life surveys including a visual analog scale
7. Evaluation of effectiveness and adverse effects of current and past medications using a visual analog scale

MAJOR OUTCOMES CONSIDERED

Utility of assessment tools and interventions

METHODOLOGY

METHODS USED TO COLLECT/SELECT EVIDENCE

Searches of Electronic Databases

DESCRIPTION OF METHODS USED TO COLLECT/SELECT THE EVIDENCE

Not stated

NUMBER OF SOURCE DOCUMENTS

Not stated

METHODS USED TO ASSESS THE QUALITY AND STRENGTH OF THE EVIDENCE

Not stated

RATING SCHEME FOR THE STRENGTH OF THE EVIDENCE

Not applicable

METHODS USED TO ANALYZE THE EVIDENCE

Review

DESCRIPTION OF THE METHODS USED TO ANALYZE THE EVIDENCE

Not stated

METHODS USED TO FORMULATE THE RECOMMENDATIONS

Not stated

RATING SCHEME FOR THE STRENGTH OF THE RECOMMENDATIONS

Not applicable

COST ANALYSIS

A formal cost analysis was not performed and published cost analyses were not reviewed.

METHOD OF GUIDELINE VALIDATION

Peer Review

DESCRIPTION OF METHOD OF GUIDELINE VALIDATION

Not stated

RECOMMENDATIONS

MAJOR RECOMMENDATIONS

Assessing Nasal Symptom Severity

By asking the patient to evaluate individual symptom severity using a 7-point visual analog scale, interval data are generated with lower measurement error and a correspondingly higher precision compared with a 5-point equal interval scale. Figure 1 in the original guideline document is an example of the type of visual analog scale that is recommended to evaluate severity of rhinitis.

Since the duration of allergic rhinitis symptoms is different in every patient, each analysis of symptom severity should specify the period during which the evaluation is being made (e.g., more than 24 hours, more than 2 weeks, or a point-in-time evaluation). It may also be helpful in some patients to distinguish patterns of symptoms (e.g., daytime or nighttime, indoor or outdoor). Recognizing these possible confounding variables, the further characterization of symptoms is left to the discretion of the physician.

Objective measurement of symptoms should be incorporated into evaluation of rhinitis severity if considered helpful by the health care professional and could include the following: (1) presence or absence of episodes of sneezing; (2) number of sneezes per episode; (3) amount of nasal tissue used during a given period; (4) amount of swelling seen on physical examination and/or anterior rhinoscopy; and (5) various rhinometric techniques.

Assessing Non-Nasal Symptom Severity

Since non-nasal symptoms are not found universally in patients with rhinitis, they are not included in the rhinitis severity scale outlined in Figure 1 in the original guideline document, which has been specifically designed to permit an evaluation of nasal symptoms. Since they are so frequently associated with rhinitis, however, they may also be evaluated, using a scale similar to that used for nasal symptoms (Figure 2 in the original guideline document). Adjustment in a treatment regimen based on severity of non-nasal symptoms can be made by the health care professional on an individual basis, similar to the adjustments recommended for nasal symptoms.

Global Assessment of Nasal and Non-nasal Symptom Severity

A global scale provides additional information about the status of the patient beyond what is found with individual symptoms. It asks the patient to globally rate the combination of the nasal and non-nasal symptoms on a 7-point scale. Unlike the scales for nasal and non-nasal symptoms, a score of 7 on the global evaluation scale indicates that the patient is having no symptoms. Overall symptoms can be rated using the scale shown in Figure 3 in the original guideline document.

Quality of Life in the Assessment of Rhinitis Severity

Quality of life is an important consideration in the evaluation and treatment of patients with allergic rhinitis. Disease-specific quality-of-life surveys for allergic rhinitis have been developed and standardized for children and adults. Such surveys facilitate the recognition of individual effects of the disease on the patient's quality of life, which may not otherwise be mentioned by patients and may be ignored or trivialized by patients and health care professionals. Use of surveys by physicians at each clinic visit can help to evaluate the effects of treatment interventions on symptom control and the patient's quality of life. In addition, patients and families learn to recognize the effects of allergic rhinitis symptoms on the quality of their life.

The visual analog scale shown in Figure 4 in the original guideline document, which assesses the patient's quality of life, can be used by the physician as

adjunctive data to support the initial evaluation of rhinitis severity based on nasal symptoms. It can also be used by the physician as a means of patient follow-up after determining the initial management of the patient. It incorporates activities and functioning during the day and sleeping at night.

The Impact of Current and Past Medications on Assessment of Rhinitis Severity

Determining past responsiveness and adverse effects from medications (including over-the-counter or herbal medications) can help guide the health care practitioner in selection of future therapeutic approaches and directly affects the evaluation of rhinitis severity. It is important therefore to determine the current and past medications that each patient has received, including whether a particular medication was either ineffective or had produced a significant adverse effect. Failure of a drug used consistently has a different significance for severity evaluation than failure of the drug due to poor compliance. Nonprescription antihistamines, topical alpha1-decongestants and cromolyn, and herbal remedies may not necessarily be reported by patients spontaneously. Long-term daily use of topical decongestants is of special concern, since they frequently produce rhinitis medicamentosa. Current use of medications for rhinitis or other conditions and their effect on rhinitis severity should be considered. A beneficial therapeutic effect on rhinitis may be seen with the use of medications for non-nasal conditions (e.g., leukotriene modifiers or orally inhaled corticosteroids). If these agents are withdrawn or the dose is decreased, an increase in symptoms of rhinitis may occur. These are variables that cannot easily be controlled for unless a sophisticated model is used to explain a large number of comorbidities and their treatment.

Rhinitis Medication Assessment

The visual analog scale shown in Figure 5 in the original guideline document can be used to evaluate medications. This scale includes those medications (including alternative medications) that the patient has used in the past for nasal and non-nasal symptoms and how effective they were (i.e., to what extent they relieved or aggravated nasal symptoms or produced adverse effects). Visual analog scales should be constructed for the effectiveness and side effect profile of each past and current nasal and non-nasal medication used by the patient.

CLINICAL ALGORITHM(S)

None provided

EVIDENCE SUPPORTING THE RECOMMENDATIONS

TYPE OF EVIDENCE SUPPORTING THE RECOMMENDATIONS

The type of evidence is not specifically stated for each recommendation.

BENEFITS/HARMS OF IMPLEMENTING THE GUIDELINE RECOMMENDATIONS

POTENTIAL BENEFITS

Overall Benefits

Accurate assessment of nasal and non-nasal symptom severity of allergic rhinitis as well as quality of life issues related to allergic rhinitis

Specific Benefits

- Classification of rhinitis severity may be used in adults or children to help determine appropriate pharmacotherapy.
- Use of surveys by physicians at each clinic visit can help to evaluate the effects of treatment interventions on symptoms control and the patient's quality of life.
- Determining past responsiveness and adverse effects from medications can help guide the health care practitioner in selection of future therapeutic approaches and directly affects the evaluation of rhinitis severity.
- The assessment and quantification of severity of symptoms of allergic rhinitis should allow for more consistent patient management and facilitation of research protocols

POTENTIAL HARMS

Not stated

QUALIFYING STATEMENTS

QUALIFYING STATEMENTS

- This parameter was edited by Dr. Nicklas in his private capacity and not in his capacity as a medical officer with the Food and Drug Administration. No official support or endorsement by the Food and Drug Administration is intended or should be inferred.
- This is a complete and comprehensive document at the current time. The medical environment is a changing environment and not all recommendations will be appropriate for all patients.
- Because this document incorporated the efforts of many participants, no single individual, including those who served on the Joint Task Force, is authorized to provide an official American College of Allergy, Asthma, and Immunology (AAAAI) or American College of Allergy, Asthma, and Immunology (ACAAI) interpretation of these practice parameters. Any request for information about or an interpretation of these practice parameters by the AAAAI or the ACAAI should be directed to the Executive Offices of the AAAAI, the ACAAI, and the Joint Council of Allergy, Asthma, and Immunology.
- These parameters are not designed for use by pharmaceutical companies in drug promotion.

IMPLEMENTATION OF THE GUIDELINE

DESCRIPTION OF IMPLEMENTATION STRATEGY

An implementation strategy was not provided.

IMPLEMENTATION TOOLS

Chart Documentation/Checklists/Forms

For information about [availability](#), see the "Availability of Companion Documents" and "Patient Resources" fields below.

INSTITUTE OF MEDICINE (IOM) NATIONAL HEALTHCARE QUALITY REPORT CATEGORIES

IOM CARE NEED

Getting Better
Living with Illness

IOM DOMAIN

Effectiveness

IDENTIFYING INFORMATION AND AVAILABILITY

BIBLIOGRAPHIC SOURCE(S)

Spector SL, Nicklas RA, Chapman JA, Bernstein IL, Berger WE, Blessing-Moore J, Dykewicz MS, Fineman SM, Lee RE, Li JT, Portnoy JM, Schuller DE, Lang D, Tilles SA. Symptom severity assessment of allergic rhinitis: part 1. Ann Allergy Asthma Immunol 2003 Aug;91(2):105-14. [14 references] [PubMed](#)

ADAPTATION

Not applicable: The guideline was not adapted from another source.

DATE RELEASED

2003 Aug

GUIDELINE DEVELOPER(S)

American Academy of Allergy, Asthma and Immunology - Medical Specialty Society
American College of Allergy, Asthma and Immunology - Medical Specialty Society
Joint Council of Allergy, Asthma and Immunology - Medical Specialty Society

SOURCE(S) OF FUNDING

Funded exclusively by the American Academy of Allergy, Asthma, and Immunology (AAAAI), the American College of Allergy, Asthma, and Immunology (ACAAI), and the Joint Council of Allergy, Asthma, and Immunology (JCAAI).

GUIDELINE COMMITTEE

Joint Task Force on Practice Parameters

COMPOSITION OF GROUP THAT AUTHORED THE GUIDELINE

Primary Authors: Sheldon L. Spector, MD; Richard A. Nicklas, MD; Jean A. Chapman, MD; I. Leonard Bernstein, MD; William E. Berger, MD; Joann Blessing-Moore, MD; Mark S. Dykewicz, MD; Stanley M. Fineman, MD; Rufus E. Lee, MD; James T. Li, MD, PhD; Jay M. Portnoy, MD; Diane E. Schuller, MD; David Lang, MD; and Stephen A. Tilles, MD

*This parameter was edited by Dr. Nicklas in his private capacity and not in his capacity as a medical officer with the Food and Drug Administration. No official support or endorsement by the Food and Drug Administration is intended or should be inferred.

FINANCIAL DISCLOSURES/CONFLICTS OF INTEREST

Not stated

GUIDELINE STATUS

This is the current release of the guideline.

GUIDELINE AVAILABILITY

Electronic copies: Available from the [Joint Council of Allergy, Asthma, and Immunology \(JCAAI\) Web site](#).

Print copies: Available from JCAAI, 50 N. Brockway, Ste 3-3 Palatine, IL 60067; E-mail: info@jcaai.org.

AVAILABILITY OF COMPANION DOCUMENTS

The following is available:

- Forms to be given to the patients. Addendum. Electronic copies: Available from the [Joint Council of Allergy, Asthma, and Immunology \(JCAAI\) Web site](#).

Print copies: Available from JCAAI, 50 N. Brockway, Ste 3-3 Palatine, IL 60067; E-mail: info@jcaai.org.

PATIENT RESOURCES

None available

NGC STATUS

This NGC summary was completed by ECRI on May 9, 2005. The information was verified by the guideline developer on May 23, 2005.

COPYRIGHT STATEMENT

This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions. Please contact the Joint Council of Allergy, Asthma, and Immunology for more information.

DISCLAIMER

NGC DISCLAIMER

The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.

All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.

Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at <http://www.guideline.gov/about/inclusion.aspx>.

NGC, AHRQ, and its contractor ECRI make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding guideline content are directed to contact the guideline developer.

© 1998-2006 National Guideline Clearinghouse

Date Modified: 9/25/2006

